PSTI Key Stats
- A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013 May 20
- Cloning: A Stem Cell Revolution? Fool May 19
- PLURISTEM THERAPEUTICS INC Financials May 14
- 3 Healthcare Stock Stories For Monday Investment Wellness May 13
- Pluristem Therapeutics' PLX cells may be effective in treating preeclampsia May 13
- Pluristem Announces Preclinical Research Shows PLX Cells May be Effective in Tre... May 13
- Preclinical Research Shows PLX Cells May be Effective in Treating Preeclampsia GlobeNewswire May 13
- PLURISTEM THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 8
- Pluristem Therapeutics announces Phase 1 trial to study PLX-PAD cells May 8
- Pluristem Carving Out Distinct Niche in Orthopedic Medicine With New Clinical Tr... May 8
PSTI Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Pluristem Therapeutic is up 19.25% over the last year vs S&P 500 Total Return up 30.17%, United Therapeutics Corporation up 57.50%, and Celgene Corporation up 80.44%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for PSTI
Pro Report PDF for PSTI
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download PSTI Pro Report PDF
Pro Strategies Featuring PSTI
Did Pluristem Therapeutic make it into our Pro Portfolio Strategies?
Pluristem Therapeutics is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas. In 2012 a procedure involving a stem cell treatment developed by Pluristem saved the life of a 7-year-old girl suffering from bone marrow aplasia.